Treatment of immunocompromised COVID‐19 patients with convalescent plasma
Monica Fung(University of California, San Francisco), Peter Chin‐Hong(University of California, San Francisco), John P. Roberts(University of California, San Francisco), Emma Bainbridge(University of California, San Francisco), Justin Teraoka, Janet Aldrich(University of California, San Francisco), Jennifer M. Babik(University of California, San Francisco), Steven R. Hays(University of California, San Francisco), Deborah S. Yokoe(Brigham and Women's Hospital), Sindhu Chandran(Cedars-Sinai Medical Center), Ashok Nambiar(University of California, San Francisco), Catherine DeVoe(University of California, San Francisco), Timothy J. Henrich(University of California, San Francisco), Christopher E. Freise(University of California, San Francisco), Annelys Roque Gardner(University of California, San Francisco)
Cited by 53
Related Papers
Liver Transplantation for Hepatocellular Carcinoma: Expansion of the Tumor Size Limits Does Not Adversely Impact Survival
|Hepatology|2001|2.3k
COVID-19 in Immunocompromised Hosts: What We Know So Far
|Clinical Infectious Diseases|2020|568
Liver Transplantation for Hepatocellular Carcinoma: Validation of the UCSF‐Expanded Criteria Based on Preoperative Imaging
|American Journal of Transplantation|2007|558
Strategies to Prevent Catheter-Associated Urinary Tract Infections in Acute Care Hospitals: 2014 Update
|Infection Control and Hospital Epidemiology|2014|520
Strategies to Prevent Surgical Site Infections in Acute Care Hospitals
|Infection Control and Hospital Epidemiology|2008|488